Your session is about to expire
← Back to Search
Cell Therapy
1 for Cardiomyopathy (CAuSMIc II Trial)
Phase 2
Waitlist Available
Research Sponsored by Mytogen, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
CAuSMIc II Trial Summary
The purpose of this study is to evaluate the safety and effectiveness of injecting myoblasts (grown from your own skeletal muscle), using a catheter device, directly into the damaged heart muscle for treatment of severe heart failure.
Eligible Conditions
- Cardiomyopathy
CAuSMIc II Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Kansas City Cardiomyopathy Questionnaire
Secondary outcome measures
Cardiovascular mortality
CAuSMIc II Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 1Experimental Treatment1 Intervention
myoblast
Group II: 2Placebo Group1 Intervention
sham injection procedure
Find a Location
Who is running the clinical trial?
Mytogen, Inc.Lead Sponsor
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger